Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HALO | CLUSTER | neutral | 2/10 | CEO Helen Torley sold $153K in stock after exercising derivative shares at $12.07, netting a substantial cashless-settle | Jul 10, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$7.7M in open-market shares over July 8-9, 2026, following option exercises. EVP Paul Mahon | Jul 10, 2026 |
| SION | CLUSTER | neutral | 4/10 | Three insiders at Sionna Therapeutics (SION) sold a total of $8.16M in shares over a 7-day window, representing 0.41% of | Jul 10, 2026 |
| CUE | PRESS-RELEASE | bullish | 6/10 | Cue Biopharma announced a $50M private placement priced at $33.21/share, led by Cormorant Asset Management with particip | Jul 9, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP Paul Mahon sold ~$1.46M in open-market UTHR shares over the past week. CEO Rothblatt's sal | Jul 9, 2026 |
| MESO | PRESS-RELEASE | mixed | 6/10 | Mesoblast reported Q1 FY2026 EPS of -$0.07, missing consensus of -$0.03 by 133%. However, the company announced full-yea | Jul 9, 2026 |
| IONS | CLUSTER | neutral | 2/10 | A cluster of insider sales at Ionis Pharmaceuticals (IONS) totaling $1.36M over a 7-day window, involving the Chief Scie | Jul 9, 2026 |
| ABEO | CLUSTER | neutral | 2/10 | Two insiders at Abeona Therapeutics (ABEO), the Chief Commercial Officer and SVP/Chief Legal Officer, conducted open-mar | Jul 9, 2026 |
| RCUS | 144 | neutral | 3/10 | Officer Juan Jaen filed Form 144 to sell 25,000 shares (approx. $749,000) under a 10b5-1 plan dated 02/27/2026. The trus | Jul 9, 2026 |
| IONS | CLUSTER | neutral | 2/10 | Three IONIS insiders (two directors and an EVP) sold a total of ~$902K in open-market transactions over a one-week perio | Jul 9, 2026 |
| ELAB | 8-K | neutral | 2/10 | PMGC Holdings Inc. (ELAB) filed an 8-K reporting the internal merger of its wholly owned subsidiary AGA Precision System | Jul 9, 2026 |
| GRDX | S-1/A | bearish | 5/10 | GridAI Technologies Corp. filed Amendment No. 1 to its S-1 registration statement to register the resale of 9,908,766 sh | Jul 9, 2026 |
| AIMD | 8-K | neutral | 3/10 | Ainos, Inc. entered into a short-term unsecured credit facility with CTBC Bank for NT$62,000,000 (~US$1.94M), bearing 2. | Jul 9, 2026 |
| IMNM | CLUSTER | neutral | 4/10 | Three Immunome insiders sold a total of ~$813K in open-market shares over a one-week window ending July 7, 2026, includi | Jul 9, 2026 |
| TVTX | 8-K | neutral | 2/10 | Travere Therapeutics announced the planned retirement of CAO Sandra Calvin after the filing of the 2026 10-K (expected F | Jul 9, 2026 |
| BHVN | 8-K | neutral | 3/10 | Biohaven announced on July 9, 2026, that CSO Dr. Bruce Car is retiring effective July 13, 2026, to transition to a part- | Jul 9, 2026 |
| QUCY | 3 | neutral | 2/10 | Louis R. Buffalino filed an initial statement of beneficial ownership (Form 3) for Quantum Cyber N.V., disclosing zero o | Jul 9, 2026 |
| TRAW | 8-K | neutral | 3/10 | Traws Pharma held its 2026 Annual Meeting on July 8, 2026, where shareholders approved all five proposals: election of s | Jul 9, 2026 |
| SION | CLUSTER | bearish | 5/10 | Three Sionna insiders sold a combined $9.57M in open-market sales over a 7-day window, including a director ($5.27M) and | Jul 9, 2026 |
| NBIX | PRESS-RELEASE | neutral | 1/10 | Neurocrine Biosciences, Inc. announced it will host a conference call on July 30, 2026 to discuss its Q2 2026 results. | Jul 9, 2026 |
| NRIX | PRESS-RELEASE | bullish | 8/10 | Nurix reported Q1 FY2026 revenue of $9.0M (consensus $15.3M, -41% miss) and EPS of -$0.81 vs consensus -$0.72 (-12.5% mi | Jul 9, 2026 |
| VOR | 3 | neutral | 2/10 | David Zaccardelli filed a Form 3 initial statement of beneficial ownership with Vor Biopharma Inc. on July 9, 2026, repo | Jul 9, 2026 |
| PRPH | 10-Q/A | bearish | 8/10 | ProPhase Labs filed Amendment No. 2 to its Q1 2026 10-Q, restating previously issued financial statements to correct mat | Jul 9, 2026 |
| IONS | 8-K | bearish | 7/10 | Ionis announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM failed its primary endpoint of CV mo | Jul 9, 2026 |
| VRAX | PRESS-RELEASE | bearish | 7/10 | Virax Biolabs is raising $3.3M through exercise of preferred investment options at a reduced price of $6/share, while is | Jul 9, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a Form 6-K reporting a routine PDMR transaction: Maya Martinez-Davis, President US, acquired 8.955 notional AD | Jul 9, 2026 |
| TAK | 6-K | neutral | 2/10 | Takeda filed its annual Corporate Governance Report, confirming compliance with all principles of the Corporate Governan | Jul 9, 2026 |
| ATHE | 6-K | neutral | 3/10 | Alterity Therapeutics received an A$3.98M R&D tax refund from the Australian government for the 2025 financial year, pro | Jul 9, 2026 |
| AZN | 6-K | bearish | 6/10 | AstraZeneca announced that the CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in transthyretin-mediated amyl | Jul 9, 2026 |
| RDY | 6-K | bearish | 5/10 | Dr. Reddy's disclosed that certain batches of semaglutide (a key metabolic therapy) were found out of specification due | Jul 9, 2026 |